Madeddu C, Neri M, Sanna E, Oppi S, Maccio A. Experimental drugs for chemotherapy- and cancer-related anemia. J Exp Pharmacol. 2021;13:593–611.

Article  PubMed  PubMed Central  Google Scholar 

Spivak JL. The anaemia of cancer: Death by a thousand cuts. Nat Rev Cancer. 2005;5:543–55.

Article  CAS  PubMed  Google Scholar 

Gilreath JA, Rodgers GM. How I treat cancer-associated anemia. Blood. 2020;136:801–13.

Article  PubMed  Google Scholar 

Chen C, Song Z, Wang W, Zhou J. Baseline anemia and anemia grade are independent prognostic factors for stage IV non-small cell lung cancer. Mol Clin Oncol. 2021;14:59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40:2293–306.

Article  PubMed  Google Scholar 

Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, et al. The next decade of immune checkpoint therapy. Cancer Discov. 2021;11:838–57.

Article  CAS  PubMed  Google Scholar 

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353–65.

Article  CAS  PubMed  Google Scholar 

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sautes-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19:307–25.

Article  CAS  PubMed  Google Scholar 

Long H, Jia Q, Wang L, Fang W, Wang Z, Jiang T, et al. Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. Cancer Cell. 2022;40(674–693): e677.

Google Scholar 

Mandula JK, Rodriguez PC. Tumor-directed dysregulation of erythroid progenitors drives immunosuppressive myeloid cells. Cancer Cell. 2022;40:597–9.

Article  CAS  PubMed  Google Scholar 

Blank U, Karlsson S. TGF-beta signaling in the control of hematopoietic stem cells. Blood. 2015;125:3542–50.

Article  CAS  PubMed  Google Scholar 

Zermati Y, Fichelson S, Valensi F, Freyssinier JM, Rouyer-Fessard P, Cramer E, et al. Transforming growth factor inhibits erythropoiesis by blocking proliferation and accelerating differentiation of erythroid progenitors. Exp Hematol. 2000;28:885–94.

Article  CAS  PubMed  Google Scholar 

Matsuzaki K, Date M, Furukawa F, Tahashi Y, Matsushita M, Sakitani K, et al. Autocrine stimulatory mechanism by transforming growth factor beta in human hepatocellular carcinoma. Cancer Res. 2000;60:1394–402.

CAS  PubMed  Google Scholar 

Han Y, Liu Q, Hou J, Gu Y, Zhang Y, Chen Z, et al. Tumor-induced generation of splenic erythroblast-like Ter-cells promotes tumor progression. Cell. 2018;173(634–648): e612.

Google Scholar 

Wang BY, Wang Y, Chen HN, Yao SY, Lai XF, Qiu Y, et al. Inhibition of TGF beta improves hematopoietic stem cell niche and ameliorates cancer-related anemia. Stem Cell Res Ther. 2021;12:65.

Article  PubMed  PubMed Central  Google Scholar 

Feng CC, Ding GX, Song NH, Li X, Wu Z, Jiang HW, et al. Paraneoplastic hormones: parathyroid hormone-related protein (PTHrP) and erythropoietin (EPO) are related to vascular endothelial growth factor (VEGF) expression in clear cell renal cell carcinoma. Tumour Biol. 2013;34:3471–6.

Article  CAS  PubMed  Google Scholar 

Jubb AM, Pham TQ, Hanby AM, Frantz GD, Peale FV, Wu TD, et al. Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol. 2004;57:504–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Greenwald AC, Licht T, Kumar S, Oladipupo SS, Iyer S, Grunewald M, et al. VEGF expands erythropoiesis via hypoxia-independent induction of erythropoietin in noncanonical perivascular stromal cells. J Exp Med. 2019;216:215–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lim S, Zhang Y, Zhang D, Chen F, Hosaka K, Feng N, et al. VEGFR2-mediated vascular dilation as a mechanism of VEGF-induced anemia and bone marrow cell mobilization. Cell Rep. 2014;9:569–80.

Article  CAS  PubMed  Google Scholar 

Xue Y, Religa P, Cao R, Hansen AJ, Lucchini F, Jones B, et al. Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proc Natl Acad Sci U S A. 2008;105:18513–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ganz T, Nemeth E. Iron balance and the role of hepcidin in chronic kidney disease. Semin Nephrol. 2016;36:87–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Busti F, Marchi G, Ugolini S, Castagna A, Girelli D. Anemia and iron deficiency in cancer patients: role of iron replacement therapy. Pharmaceuticals (Basel). 2018;11:94.

Article  CAS  PubMed  Google Scholar 

Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011–23.

Article  CAS  PubMed  Google Scholar 

Gilreath JA, Stenehjem DD, Rodgers GM. Total dose iron dextran infusion in cancer patients: is it SaFe2+? J Natl Compr Canc Netw. 2012;10:669–76.

Article  CAS  PubMed  Google Scholar 

Theurl I, Theurl M, Seifert M, Mair S, Nairz M, Rumpold H, et al. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood. 2008;111:2392–9.

Article  CAS  PubMed  Google Scholar 

Wessling-Resnick M. Iron homeostasis and the inflammatory response. Annu Rev Nutr. 2010;30:105–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fraenkel PG. Anemia of inflammation: a review. Med Clin North Am. 2017;101:285–96.

Article  PubMed  Google Scholar 

Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117:4425–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang AS, Enns CA. Molecular mechanisms of normal iron homeostasis. Hematology Am Soc Hematol Educ Program 2009;1:207–14.

Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007;12:231–42.

Article  CAS  PubMed  Google Scholar 

Rivera S, Liu L, Nemeth E, Gabayan V, Sorensen OE, Ganz T. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood. 2005;105:1797–802.

Article  CAS  PubMed  Google Scholar 

Falkensammer CE, Thurnher M, Leonhartsberger N, Ramoner R. C-reactive protein is a strong predictor for anaemia in renal cell carcinoma: role of IL-6 in overall survival. BJU Int. 2011;107:1893–8.

Article  CAS  PubMed  Google Scholar 

Madeddu C, Gramignano G, Kotsonis P, Coghe F, Atzeni V, Scartozzi M, et al. Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: key role of interleukin-6. Haematologica. 2018;103:e388–91.

Article  PubMed  PubMed Central  Google Scholar 

Nieken J, Mulder NH, Buter J, Vellenga E, Limburg PC, Piers DA, et al. Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood. 1995;86:900–5.

Article  CAS  PubMed  Google Scholar 

Mori K, Fujimoto-Ouchi K, Onuma E, Noguchi M, Shimonaka Y, Yasuno H, et al. Novel models of cancer-related anemia in mice inoculated with IL-6-producing tumor cells. Biomed Res. 2009;30:47–51.

Article  CAS  PubMed